Veracyte, Inc.
VCYT
株式のランク
#4358
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
株価
$44.93
時価総額
$3.61B
変化（1日）
2.57%
変化（1年）
22.59%
国
US
取引 Veracyte, Inc. (VCYT)
カテゴリー
Healthcare
Veracyte, Inc.（VCYT）の利益
Jun 2026 時点の利益 TTM: $108.94M
Veracyte, Inc. の最新の財務報告によると、同社の現在の利益は $108.94M です。2023 年には $-76.61M の利益を上げ、これは 2022 年の利益 $-36.43M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Veracyte, Inc. の利益の推移（2011 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $108.94M | 323.17% |
| 2024 | $25.74M | -133.60% |
| 2023 | $-76.61M | 110.32% |
| 2022 | $-36.43M | -55.39% |
| 2021 | $-81.65M | 133.89% |
| 2020 | $-34.91M | 177.08% |
| 2019 | $-12.60M | -45.22% |
| 2018 | $-23.00M | -25.82% |
| 2017 | $-31.00M | -1.13% |
| 2016 | $-31.36M | -6.96% |
| 2015 | $-33.70M | 14.74% |
| 2014 | $-29.37M | 14.83% |
| 2013 | $-25.58M | 37.17% |
| 2012 | $-18.65M | 29.10% |
| 2011 | $-14.45M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $7.61B | 6,884.58% |
US
|
|
| $4.76B | 4,271.21% |
US
|
|
| $-252.70M | -331.96% |
US
|
|
| - | - |
CN
|
|
| $1.66B | 1,421.94% |
US
|
